Reported about 23 hours ago
ResMed Inc., based in San Diego, has demonstrated strong stock performance, trading at $293.81 before recently dipping slightly. With a market cap of $39.6 billion, it outperformed the Health Care Select Sector SPDR Fund by gaining 7.1% over three months and 18.1% in 2025, while its rival Becton, Dickinson and Company has experienced a notable decline. After showcasing impressive Q4 results, ResMed's stock is actively rated as a 'Moderate Buy' by analysts, reflecting investor confidence.
Source: YAHOO